Med2Date — Clinical Guidelines
Home Geriatric Medicine Dementia with Lewy Bodies (DLB)

Dementia with Lewy Bodies (DLB)

Last updated 1 Jun 2026 · Geriatric medicine

📋 Key Information Summary

📋
  • Dementia with Lewy Bodies (DLB) is the second most common neurodegenerative dementia after Alzheimer disease, accounting for 10–15% of all dementia cases at autopsy in Australia.
  • DLB is a synucleinopathy characterised by the core clinical triad of progressive cognitive decline (especially attention and visuospatial deficits), recurrent well-formed visual hallucinations, and spontaneous parkinsonism.
  • Cognitive fluctuations — episodes of staring, prolonged daytime drowsiness, and variable alertness — are a hallmark feature that distinguishes DLB from Alzheimer disease.
  • REM sleep behaviour disorder (RBD), often preceding dementia by years or decades, is a strong supportive feature and should prompt screening for a synucleinopathy.
  • Severe neuroleptic (antipsychotic) sensitivity occurs in up to 50% of DLB patients and can cause irreversible parkinsonism, neuroleptic malignant syndrome, or death — typical antipsychotics (haloperidol) are CONTRAINDICATED.
  • If antipsychotic treatment for behavioural or psychotic symptoms is unavoidable, quetiapine (low dose) or clozapine may be used cautiously under specialist supervision.
  • Cholinesterase inhibitors (rivastigmine, donepezil) are first-line for cognition and can also improve hallucinations and apathy; rivastigmine is PBS-listed for DLB/PDD in Australia.
  • Parkinsonism should be managed conservatively — levodopa is preferred over dopamine agonists; start low and titrate slowly, monitoring for worsening hallucinations.
  • DAT-SPECT (DaTscan) showing reduced striatal uptake is a supportive biomarker and is available in major Australian centres (MBS-eligible under specific criteria).
  • Aboriginal and Torres Strait Islander Australians may have reduced access to specialist diagnostic services and culturally appropriate cognitive assessments; early referral to aged-care and Indigenous health services is essential.
  • Multidisciplinary care involving geriatrics, neurology, psychiatry, sleep medicine, and allied health is recommended to address the complex symptom overlap in DLB.
  • Falls risk is elevated due to parkinsonism and autonomic dysfunction — implement falls prevention strategies early.

Introduction & Australian Epidemiology

Dementia with Lewy Bodies (DLB) is the second most common cause of neurodegenerative dementia in older Australians, accounting for approximately 10–15% of all dementia cases identified at autopsy. It is classified as an alpha-synucleinopathy alongside Parkinson disease dementia (PDD), sharing the same underlying pathology of Lewy bodies (intraneuronal aggregates of misfolded alpha-synuclein) and Lewy neurites distributed throughout the cerebral cortex, brainstem, and limbic structures.

DLB is critically important to recognise because its management differs substantially from Alzheimer disease (AD). In particular, patients with DLB are exquisitely sensitive to antipsychotic medications — a single dose of haloperidol can provoke severe, irreversible parkinsonism, prolonged sedation, or neuroleptic malignant syndrome (NMS). Misdiagnosis as AD or psychosis of ageing may therefore lead to iatrogenic harm.

The distinction between DLB and PDD is operationally defined by the "one-year rule": if cognitive symptoms precede or emerge within 12 months of parkinsonism, the diagnosis is DLB; if parkinsonism precedes cognitive decline by more than 12 months, the diagnosis is PDD. In practice, both conditions share overlapping neuropathology and clinical management principles.

Australian Epidemiology

  • Prevalence estimates suggest approximately 30,000–50,000 Australians are living with DLB, though it remains substantially underdiagnosed.
  • Affects men slightly more often than women (M:F ratio approximately 1.5:1).
  • Age of onset is typically 50–85 years, with a mean onset around 70 years — younger than typical Alzheimer disease.
  • DLB is associated with a more rapid cognitive and functional decline than AD, with a shorter median survival from diagnosis (approximately 5–8 years).
  • The AIHW reports that dementia is the second leading cause of death in Australia; DLB contributes significantly to this burden but is often misclassified.
  • Carer burden is disproportionately high due to behavioural symptoms, fluctuating cognition, falls, and sleep disturbance.
⚠️
Diagnostic delay is common: Many DLB patients are initially misdiagnosed with Alzheimer disease, vascular dementia, or late-onset psychosis. A high index of suspicion is required, particularly when cognitive fluctuations, early hallucinations, or REM sleep behaviour disorder are present.

Core Clinical Features

The diagnosis of DLB is based on the 2017 revised consensus criteria from the DLB Consortium (McKeith et al., 2017). Features are classified as core clinical features, supportive features, and indicative biomarkers.

Core Clinical Features

Feature Description Key Clinical Points
Progressive cognitive decline Prominent in early stages, sufficient to impair daily function Attention, executive function, and visuospatial abilities are disproportionately affected compared to memory in early disease; memory retrieval may improve with cues
Cognitive fluctuations Spontaneous variations in attention, alertness, and cognitive performance Episodes of staring into space, prolonged daytime somnolence, lethargy, or disorganised speech alternating with lucid intervals; may be mistaken for transient ischaemic attacks or delirium
Recurrent visual hallucinations Well-formed, detailed, and recurrent Often involve people (including children), animals, or small figures; patients may describe them vividly; typically occur early in the disease course, unlike AD where hallucinations suggest later or more severe stages
Spontaneous parkinsonism Bradykinesia, rigidity, rest tremor (less common), postural instability Must not be attributable to medications or another disorder; symmetric onset is more common than the asymmetric onset typical of Parkinson disease; tremor may be absent

Supportive Clinical Features

  • REM sleep behaviour disorder (RBD) — may precede dementia by decades; strongly associated with synucleinopathies
  • Severe neuroleptic sensitivity — see dedicated section below
  • Postural instability and repeated falls
  • Syncopal or unexplained episodes of transient loss of consciousness
  • Autonomic dysfunction — orthostatic hypotension, constipation, urinary incontinence, erectile dysfunction
  • Hypersomnia (reduced daytime alertness not explained by sleep apnoea)
  • Hyposmia / anosmia
  • Systematised delusions
  • Depression and anxiety

Probable vs Possible DLB Diagnosis

✅
Probable DLB: Requires ≥2 core features, OR 1 core feature plus ≥1 indicative biomarker.
Possible DLB: Requires 1 core feature with no indicative biomarker, OR ≥1 indicative biomarker with no core features.

Indicative Biomarkers

  • DAT-SPECT (DaTscan): Reduced dopamine transporter uptake in the basal ganglia — distinguishes DLB from AD
  • 123I-MIBG myocardial scintigraphy: Reduced heart-to-mediastinum ratio indicating cardiac sympathetic denervation
  • Polysomnography confirming REM sleep without atonia

Low-likelihood Features

The presence of another condition sufficient to account for the clinical picture (e.g., cerebrovascular disease on neuroimaging, or another neurodegenerative disorder) makes DLB less likely. Absence of parkinsonism for more than 5 years after cognitive onset also lowers diagnostic probability.

REM Sleep Behaviour Disorder

REM sleep behaviour disorder (RBD) is a parasomnia characterised by loss of normal REM atonia with resultant dream-enacting behaviours, which may include talking, shouting, punching, kicking, and falling out of bed. The behaviours are often violent and may result in injury to the patient or bed partner.

Relevance to DLB

  • RBD is present in approximately 70–80% of patients with DLB, making it the most common sleep disturbance in this population.
  • Idiopathic RBD (iRBD) is now recognised as an early-stage synucleinopathy: longitudinal studies show that 80–90% of patients with iRBD will eventually develop a defined synucleinopathy (DLB, PDD, or multiple system atrophy) over 10–15 years.
  • RBD may precede cognitive symptoms in DLB by years to decades, providing a critical window for early identification and potential disease-modifying intervention.
  • In older adults presenting with new-onset RBD, clinicians should screen for cognitive impairment and parkinsonism at baseline and follow up annually.

Diagnosis

Definitive diagnosis requires polysomnography (PSG) demonstrating REM sleep without atonia (RSWA) combined with a clinical history of dream-enacting behaviour. In Australia, PSG is available through public and private sleep medicine services; referral to a sleep physician is recommended.

Essential Polysomnography (PSG) Gold standard — confirms REM sleep without atonia (RSWA) and excludes obstructive sleep apnoea as a mimic. Available at major metropolitan sleep laboratories across Australia.
Available REM Sleep Behaviour Disorder Screening Questionnaire (RBDSQ) Validated screening tool; score ≥5 warrants PSG referral. Can be administered in primary care.

Management of RBD

💊
Melatonin
Circadin® · Generic · Melatonin receptor agonist
Adult dose 2–12 mg PO nocte (start 2 mg, titrate up); sustained-release formulation preferred
Paediatric dose Not typically applicable for this indication
Renal adjustment No specific adjustment required
Hepatic adjustment Use with caution; reduced clearance in severe hepatic impairment
PBS status ✘ Not PBS-listed for RBD
💊
Clonazepam
Rivotril® · Generic · Benzodiazepine
Adult dose 0.25–2 mg PO nocte (start 0.25 mg)
Key cautions Avoid in DLB patients where possible — risk of excessive sedation, falls, respiratory depression, and worsening cognitive function. Use only if melatonin fails.
PBS status ✔ PBS General Benefit
⚠️
Bed partner safety: Advise non-pharmacological measures including padded bed rails, mattress on the floor, removal of bedside objects, and sleeping in separate beds if violence occurs. Bed partners should be assessed for injury risk.

Neuroleptic Sensitivity

Severe neuroleptic sensitivity is one of the most clinically important features of DLB and is classified as a supportive feature in the consensus diagnostic criteria. It is potentially life-threatening and represents a key reason why accurate DLB diagnosis is essential before any antipsychotic prescribing.

Mechanism

The underlying mechanism relates to the severe nigrostriatal dopaminergic deficit already present in DLB. Dopamine D2-receptor antagonism by typical (first-generation) and many atypical (second-generation) antipsychotics precipitates or worsens extrapyramidal symptoms, rigidity, and in severe cases, neuroleptic malignant syndrome (NMS). The degree of striatal dopaminergic loss in DLB exceeds that in Parkinson disease, explaining the heightened sensitivity.

Prevalence and Severity

Mild–Moderate
Extrapyramidal Reactions
Worsening parkinsonism, rigidity, bradykinesia, tremor — may occur within days of antipsychotic initiation
Setting: General practice / Aged care
Severe
Prolonged Sedation & Immobility
Excessive somnolence, reduced consciousness, inability to mobilise, aspiration risk — may persist for weeks after withdrawal of the offending agent
Setting: Hospital admission
Life-threatening
Neuroleptic Malignant Syndrome (NMS)
Hyperthermia (>38.5°C), severe rigidity, autonomic instability, altered consciousness, elevated CK, multi-organ failure — mortality in DLB-NMS exceeds 50%
Setting: ICU / Emergency
🚨
ABSOLUTE CONTRAINDICATION: Typical antipsychotics (haloperidol, chlorpromazine, droperidol) are absolutely contraindicated in suspected or confirmed DLB. Even a single dose can be fatal. Haloperidol must not be used for behavioural management or procedural sedation in these patients. Ensure all medical records, medication charts, and advance care directives clearly document antipsychotic sensitivity.

Antipsychotics to Avoid

Medication Risk in DLB Notes
Haloperidol HIGHEST — AVOID Most commonly implicated in fatal sensitivity reactions; strong D2 antagonism
Chlorpromazine HIGH — AVOID First-generation antipsychotic with potent D2/D1 blockade
Risperidone HIGH — AVOID Higher EPS risk among atypicals; severe reactions documented in DLB
Olanzapine MODERATE — USE WITH EXTREME CAUTION Lower EPS risk but sensitivity reactions still reported
Quetiapine LOWEST RISK (if antipsychotic required) Weak D2 binding; may be used cautiously at low doses under specialist supervision
Pimavanserin Selective 5-HT2A inverse agonist Not yet PBS-listed in Australia; under investigation for PPD/DLB psychosis; minimal D2 activity

Management if Antipsychotic Sensitivity Occurs

  1. Immediate cessation of the offending antipsychotic
  2. Supportive care: IV fluids, cooling for hyperthermia, monitoring in HDU/ICU if NMS
  3. Dantrolene 1–2.5 mg/kg IV for NMS (may be available in hospital pharmacies; authority through TGA Special Access Scheme if needed)
  4. Bromocriptine 2.5 mg PO/NG TDS for NMS (dopamine agonist to counter D2 blockade)
  5. Document the reaction clearly in the patient's medical record and My Health Record
  6. Report to TGA via the Adverse Event Reporting System
⚠️
Aged-care alert: Residents in Australian Residential Aged Care Facilities (RACFs) with DLB may be inadvertently prescribed antipsychotics for "behavioural and psychological symptoms of dementia" (BPSD). Deprescribing antipsychotics in DLB should be a priority. The RACGP's dementia clinical guide and the Dementia Behaviour Management Advisory Service (DBMAS) can provide support.

Management of Cognition, Psychosis and Parkinsonism

Management of DLB requires a nuanced approach addressing three interconnected domains — cognition, psychosis/behavioural disturbance, and parkinsonism — as treatment of one domain may worsen another. A multidisciplinary team approach involving geriatric medicine, neurology, psychiatry, sleep medicine, physiotherapy, occupational therapy, speech pathology, and neuropsychology is recommended.

Step-wise Management Approach

1
Optimise Non-pharmacological Strategies
Structured routine, familiar environment, carer education, sensory stimulation, music therapy, occupational therapy for ADLs, physiotherapy for balance and falls prevention, sleep hygiene
2
Initiate Cholinesterase Inhibitor for Cognition
Rivastigmine or donepezil as first-line; may also benefit hallucinations, apathy, and fluctuations
3
Address Psychosis Non-pharmacologically First
Identify and treat delirium triggers (UTI, constipation, pain, medications); optimise environment; carer education on responding to hallucinations
4
Pharmacotherapy for Psychosis if Distressing or Dangerous
Low-dose quetiapine under specialist guidance; avoid typical antipsychotics
5
Levodopa for Disabling Parkinsonism
Start low (50 mg TDS), titrate slowly; monitor for worsening hallucinations

Cognition — Cholinesterase Inhibitors

💊
Rivastigmine
Exelon® · Generic · Acetylcholinesterase / Butyrylcholinesterase inhibitor
Adult dose (oral) 1.5 mg PO BD with food → increase by 1.5 mg BD every 2 weeks → target 3–6 mg BD
Adult dose (transdermal) 4.6 mg/24 h patch → 9.5 mg/24 h → 13.3 mg/24 h (change daily)
Paediatric dose Not indicated
Renal adjustment No adjustment required
Hepatic adjustment Use with caution; monitor for increased adverse effects
Key side effects Nausea, vomiting, diarrhoea, anorexia (GI effects reduced with transdermal patch); bradycardia; vivid dreams
PBS status ✔ PBS Authority Required — DLB/PDD
💊
Donepezil
Aricept® · Generic · Acetylcholinesterase inhibitor
Adult dose 5 mg PO nocte → increase to 10 mg PO nocte after 4–6 weeks
Renal adjustment No adjustment required
Hepatic adjustment Avoid in severe hepatic impairment (Child-Pugh C)
Key cautions GI side effects less than rivastigmine; risk of bradycardia — avoid with beta-blockers; insomnia if given in the morning
PBS status ✔ PBS Authority Required — dementia
💊
Memantine
Ebixa® · Generic · NMDA receptor antagonist
Adult dose 5 mg PO daily → increase by 5 mg weekly → target 10 mg BD (or 20 mg daily as extended-release)
Renal adjustment Max 5 mg BD if eGFR 5–29 mL/min
Evidence in DLB Limited evidence; may be considered as adjunct to cholinesterase inhibitor; some studies suggest modest benefit in fluctuations
PBS status ⚠ PBS Authority Required — moderate-to-severe AD only

Psychosis — Pharmacological Management

Pharmacological treatment of psychosis in DLB should only be considered when symptoms are distressing to the patient, pose a safety risk, or are refractory to non-pharmacological measures and optimisation of cholinesterase inhibitor therapy.

💊
Quetiapine
Seroquel® · Generic · Atypical antipsychotic (low D2 affinity)
Adult dose Start 12.5 mg PO nocte → titrate by 12.5–25 mg every 3–5 days → typical range 25–100 mg/day in 1–2 divided doses
Key cautions Still carries some risk of worsening parkinsonism and sedation; monitor closely for EPS; orthostatic hypotension; falls risk; QTc prolongation
PBS status ⚠ PBS Authority Required — schizophrenia, bipolar disorder
💊
Clozapine
Clozaril® · Generic · Atypical antipsychotic
Adult dose Start 6.25–12.5 mg PO daily → titrate by 12.5 mg increments weekly → typical range 12.5–50 mg/day in DLB
Key cautions Requires mandatory blood monitoring under Clozapine Patient Monitoring Service (CPMS) — risk of agranulocytosis (1–2%); sedation; metabolic effects; constipation (can be severe in DLB with autonomic dysfunction); hypersalivation
Evidence Best evidence base for psychosis in Parkinson disease; extrapolated to DLB; effective at lower doses than used in schizophrenia
PBS status ✘ Authority Required — treatment-resistant schizophrenia (not PBS for DLB)
💡
Cholinesterase inhibitors for psychosis: Before initiating antipsychotic therapy, ensure the patient is on an optimised dose of a cholinesterase inhibitor (e.g., rivastigmine 6 mg BD). Cholinesterase inhibitors can improve hallucinations and delusions in 30–50% of DLB patients, potentially avoiding the need for antipsychotics altogether.

Parkinsonism — Management

Parkinsonism in DLB is frequently less responsive to dopaminergic therapy than in idiopathic Parkinson disease, and treatment may exacerbate hallucinations and confusion. The goal is functional improvement (mobility, ADLs), not complete symptom resolution.

💊
Levodopa / Carbidopa
Sinemet® · Kinson® · Generic
Adult dose Start levodopa 50 mg/carbidopa 12.5 mg PO TDS with food → titrate by 50 mg levodopa increments every 1–2 weeks → typical range 100–300 mg levodopa/day in divided doses
Key cautions Start low, go slow; ~30% of DLB patients will have a meaningful motor response; monitor for worsening hallucinations and confusion; orthostatic hypotension
PBS status ✔ PBS General Benefit
⚠️
Avoid dopamine agonists in DLB: Dopamine agonists (pramipexole, ropinirole, rotigotine) carry a higher risk of hallucinations, confusion, impulse control disorders, and excessive daytime somnolence in DLB. They are generally not recommended. If used at all, this should be under strict specialist supervision only.

Behavioural and Psychological Symptoms (BPSD)

Non-pharmacological strategies are the cornerstone of BPSD management in DLB, in line with the ACSQHC NSQHS Standards and the Dementia in General Practice clinical guide (RACGP).

Non-pharmacological
  • Structured daily routine and environment
  • Carer education and support (Carers Australia, Dementia Australia)
  • Music therapy, art therapy, sensory stimulation
  • Management of constipation, pain, and sleep hygiene
  • Home safety assessment and falls prevention
  • Respite care and carer mental health support
Pharmacological (last resort)
  • Citalopram 10–20 mg daily (for depression/anxiety — avoid higher doses due to QTc risk)
  • Mirtazapine 15–30 mg nocte (for insomnia and appetite, sedative effect may be beneficial)
  • Quetiapine 12.5–100 mg/day (for psychosis, if essential — see above)
  • Avoid benzodiazepines (falls, paradoxical agitation, cognitive worsening)
  • Avoid anticholinergic medications (worsen cognition)

Investigations & Diagnostic Workup

The diagnosis of DLB is primarily clinical, supported by investigations that exclude alternative diagnoses and identify indicative biomarkers.

Essential Investigations

Essential Cognitive assessment MoCA (Montreal Cognitive Assessment) is preferred over MMSE for DLB due to its sensitivity to attention/executive/visuospatial deficits. Score <26 warrants further evaluation. Free to use; can be administered in primary care.
Essential CT or MRI brain Exclude vascular pathology, normal pressure hydrocephalus, subdural haematoma, space-occupying lesions. MRI preferred (MBS Item 63092/63095). May show relative medial temporal lobe preservation compared to AD.
Essential Blood tests FBC, EUC, LFTs, TFTs, vitamin B12, folate, calcium, glucose, syphilis serology, HIV (if risk factors) — exclude reversible and metabolic causes of cognitive impairment. All available on MBS.
Available DAT-SPECT (DaTscan) 123I-ioflupane SPECT imaging of dopamine transporters; demonstrates reduced striatal uptake in DLB (positive) vs normal uptake in AD (negative). Available at major nuclear medicine centres (MBS Item 61418). Results support but do not confirm diagnosis.
Available 123I-MIBG myocardial scintigraphy Reduced heart-to-mediastinum ratio indicates cardiac sympathetic denervation, a supportive biomarker for DLB. Available at limited specialist centres in Australia.
Available Polysomnography (PSG) Confirms REM sleep without atonia; essential if RBD is suspected. Available through public and private sleep medicine services. MBS Item 12250 (full PSG).
Referral Neuropsychological assessment Detailed cognitive profiling showing characteristic pattern: impaired attention, executive dysfunction, visuospatial deficits with relatively preserved (or cue-responsive) episodic memory. Essential for diagnostic certainty. Referral to clinical neuropsychologist.
Specialist CSF biomarkers (amyloid-β, tau, alpha-synuclein seed amplification assay) CSF alpha-synuclein seed amplification assay (SAA) is an emerging biomarker with high sensitivity for synucleinopathies; available through research centres. CSF AD markers (low Aβ42, elevated p-tau) may indicate mixed AD/DLB pathology.

Diagnostic Imaging — Pearls

  • Relative preservation of medial temporal lobes on MRI (hippocampal volume) compared to AD — supportive but not diagnostic
  • Occipital hypoperfusion/hypometabolism on SPECT/PET — characteristic pattern distinguishing DLB from AD
  • FDG-PET: Occipital cortex and posterior cingulate "island" sign (relatively preserved posterior cingulate with impaired occipital cortex) — increasingly available at major PET centres

Special Populations

👴

Elderly (≥80 years)

All medications Start at lowest possible dose and titrate very slowly; increased sensitivity to cholinesterase inhibitors (GI effects, bradycardia) and antipsychotics; increased falls risk with parkinsonism and orthostatic hypotension
Anticholinergic burden Review all medications using the Anticholinergic Cognitive Burden (ACB) Scale; deprescribe agents with anticholinergic properties (e.g., oxybutynin, amitriptyline, promethazine) as these worsen cognition
Rivastigmine transdermal patch Preferred over oral formulation in elderly — reduced GI side effects and simpler dosing
🫘

Renal Impairment

Rivastigmine No dose adjustment required; metabolised by esterases, not renally cleared
Memantine Reduce dose if eGFR 5–29 mL/min (max 5 mg BD); avoid if eGFR <5 mL/min
Clozapine Use with caution; accumulation of metabolites; enhanced monitoring required
🫁

Hepatic Impairment

Donepezil Avoid in severe hepatic impairment (Child-Pugh C); use with caution in moderate impairment
Quetiapine Extensively hepatically metabolised; dose reduction may be needed; monitor closely
Rivastigmine No specific dose adjustment; monitor for increased adverse effects
🧒

Paediatric / Young-onset

General DLB is exceptionally rare in individuals under 50 years. If young-onset dementia is suspected, consider genetic testing (GBA, SNCA, LRRK2 mutations), referral to a specialist dementia service, and genetic counselling. Young-onset DLB may present with more prominent psychiatric features and diagnostic delay is common.
🛡️

Immunocompromised

General DLB itself does not confer immunocompromise; however, if clozapine is used, the risk of neutropenia is compounded by concurrent use of myelosuppressive agents. Mandatory FBC monitoring via CPMS applies.
Aboriginal and Torres Strait Islander Health

Aboriginal and Torres Strait Islander Australians experience a disproportionate burden of dementia, with onset occurring at younger ages and prevalence estimated to be 3–5 times higher than in the non-Indigenous population. While most research has focused on Alzheimer disease and vascular dementia, the burden of DLB and other synucleinopathies in Indigenous Australians remains poorly characterised due to diagnostic underascertainment.

Diagnostic access
Specialist diagnostic services (DaTscan, neuropsychology, sleep medicine) are concentrated in metropolitan centres, creating significant barriers for Indigenous Australians living in regional and remote communities. Telehealth and visiting specialist services through the Royal Flying Doctor Service and Indigenous health programmes should be leveraged.
Cultural considerations in cognitive assessment
Standard cognitive screening tools (MoCA, MMSE) may not be culturally appropriate for Aboriginal and Torres Strait Islander peoples. The Kimberley Indigenous Cognitive Assessment (KICA) tool has been validated for use in remote Indigenous communities and should be preferred where available.
Early onset and younger demographics
Indigenous Australians develop dementia at younger ages (often in the 50s and 60s); clinicians should maintain a low threshold for cognitive screening in younger Indigenous adults presenting with cognitive, behavioural, or motor symptoms.
Medication access
PBS medicines including rivastigmine and donepezil are available through Remote Area Aboriginal Health Services. Transdermal rivastigmine may be preferable in communities with limited pharmacy access as adherence is simplified. Ensure regular medication supply through community-controlled health services.
Carer support and community
The concept of dementia care in Indigenous communities involves extended family and Elders. Dementia Australia offers specific resources, and the National Aboriginal Community Controlled Health Organisation (NACCHO) can link to local services. Avoid removal from community for care unless absolutely necessary, as this causes significant distress.
Advance care planning
Advance care planning should be initiated early, with culturally appropriate conversations involving family and Elders. The national My Values platform has been adapted for Indigenous contexts. Ensure discussions respect cultural obligations around end-of-life care and decision-making.
📋
Resources: Dementia Australia — Aboriginal and Torres Strait Islander dementia support programme; AIHW — Dementia among Indigenous Australians; Kimberley Indigenous Cognitive Assessment (KICA) — available at kimberleyhealthyageing.com.au; NACCHO — community-controlled health service locator.

📚 References

  1. 1. McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology. 2017;89(1):88–100.
  2. 2. Walker Z, Possin KL, Boeve BF, Aarsland D. Lewy body dementias. Lancet. 2015;386(10004):1683–1697.
  3. 3. Stinton C, McKeith I, Taylor JP, et al. Pharmacological management of Lewy body dementia: a systematic review and meta-analysis. Am J Psychiatry. 2015;172(8):731–742.
  4. 4. Boeve BF. REM sleep behavior disorder: Updated review of the core features, the RBD-neurodegenerative disease association, evolving concepts, controversies, and future directions. Ann N Y Acad Sci. 2010;1184:15–54.
  5. 5. American Academy of Sleep Medicine. International Classification of Sleep Disorders. 3rd ed, text revision. Darien, IL: AASM; 2023.
  6. 6. Australian Institute of Health and Welfare. Dementia in Australia. Cat. no. AGE 87. Canberra: AIHW; 2023.
  7. 7. Royal Australian College of General Practitioners. Clinical guide: Dementia. Melbourne: RACGP; 2023. Available at: www.racgp.org.au.
  8. 8. Dementia Behaviour Management Advisory Service (DBMAS). Clinical practice guidelines for the management of behavioural and psychological symptoms of dementia (BPSD). Canberra: Australian Government Department of Health; 2022.
  9. 9. Smith T, Gilliam D, Giummarra J, et al. Dementia among Aboriginal and Torres Strait Islander peoples: a systematic review. Australas J Ageing. 2022;41(2):e107–e120.
  10. 10. Lo K, Su Q, Khaw KY, et al. The Kimberley Indigenous Cognitive Assessment (KICA): development of a culturally appropriate screening tool. Australas Psychiatry. 2020;28(3):287–293.
  11. 11. Taylor JP, McKeith IG, Burn DJ, et al. New evidence on the management of Lewy body dementia. Lancet Neurol. 2020;19(2):157–169.
  12. 12. Australian Commission on Safety and Quality in Health Care (ACSQHC). National Safety and Quality Health Service Standards. 2nd ed. Sydney: ACSQHC; 2021.
  13. 13. Connors MH, Quinto L, McKeith I, et al. Non-pharmacological interventions for Lewy body dementia: a systematic review. Psychol Med. 2018;48(11):1749–1758.
  14. 14. Dementia Australia. Aboriginal and Torres Strait Islander people and dementia. Fact sheet. Melbourne: Dementia Australia; 2023. Available at: www.dementia.org.au.
  15. 15. Matar E, Shine JM, Halliday GM, Lewis SJG. Cognitive fluctuations in Lewy body dementia: towards a pathophysiological framework. Brain. 2020;143(2):387–398.
for PBS scripts. Utilise ACCHS pharmacies and Remote Area Aboriginal Health Worker programs for medication supply in remote areas. Avoid initiating benzodiazepines; support holistic pain management including community-based exercise programs.
Preventive health
Promote bone health: encourage vitamin D supplementation (1000 IU daily in deficient individuals), smoking cessation support, reduction of alcohol intake, and weight-bearing exercise. MBS Item 715 health checks provide a structured opportunity to assess bone health, screen for osteoporosis risk factors, and discuss musculoskeletal health in a culturally safe context.

Quick Reference: Differential Diagnosis at a Glance

Costovertebral dysfunction
Paracetamol ± NSAID; manual therapy
2–6 weeks
Provocable on palpation; no red flags
Thoracic compression fracture
Paracetamol; ± calcitonin; DXA + osteoporosis Rx
6–12 weeks healing
Elderly; osteoporosis; acute onset
ACS (posterior MI)
Aspirin 300 mg, GTN, heparin; urgent PCI
Time-critical
ECG, troponin; CV risk factors
Aortic dissection
IV labetalol; urgent CT aortogram; surgery (Type A)
Time-critical
Tearing pain; BP differential >20 mmHg
Vertebral osteomyelitis
IV antibiotics (vancomycin + ceftriaxone initially); ID consult
6 weeks IV antibiotics
Fever, elevated CRP, IV drug use
Biliary colic / cholecystitis
Paracetamol ± morphine; lap cholecystectomy
Surgical within 72 h (cholecystitis)
RUQ/infrascapular; post-prandial; RUQ US

📚 References

  1. 1. Briggs AM, Smith AJ, Straker LM, Bragge P. Thoracic spine pain in the general population: prevalence, incidence and associated factors in children, adolescents and adults. A systematic review. BMC Musculoskelet Disord. 2009;10:77.
  2. 2. National Health and Medical Research Council (NHMRC). Evidence-based management of acute musculoskeletal pain. Canberra: NHMRC; 2003 (updated 2020).
  3. 3. Australian Institute of Health and Welfare (AIHW). Aboriginal and Torres Strait Islander Health Performance Framework: Summary report 2023. Canberra: AIHW; 2023.
  4. 4. Deyo RA, Rainville J, Kent DL. What can the history and physical examination tell us about low back pain? JAMA. 1992;268(6):760–765.
  5. 5. Stochkendahl MJ, Kjaer P, Hartvigsen J, et al. National Clinical Guidelines for non-surgical treatment of patients with recent onset low back pain or lumbar radiculopathy. Europ Spine J. 2018;27(1):60–75.
  6. 6. Erwin WM, Jackson PC, Homonko DA. Innervation of the human costovertebral joint: implications for clinical back pain syndromes. J Manipulative Physiol Ther. 2000;23(6):395–403.
  7. 7. Royal Australian College of General Practitioners (RACGP). Guidelines for preventive activities in general practice. 9th edn. Melbourne: RACGP; 2018 (updated 2023).
  8. 8. Hirsch JA, Singh V, Falco FJE, et al. Thoracic facet joint interventions. Pain Physician. 2016;19(4):E581–E593.
  9. 9. Erwin WM, Jackson PC. The costovertebral joint: anatomy, biomechanics, and clinical significance in thoracic back pain syndromes. J Can Chiropr Assoc. 2003;47(2):112–120.
  10. 10. Strayer RJ, Gunnerson JM, Brown LH, et al. Aortic dissection: clinical features, diagnosis, and management. Aust Crit Care. 2019;32(2):144–153.
  11. 11. Ombregt L. A system of orthopaedic medicine. 3rd edn. Edinburgh: Churchill Livingstone Elsevier; 2013. Chapter 18: Thoracic spine.
  12. 12. Lin CC, Chen KH, Li DM, et al. Characteristics and outcomes of patients presenting with thoracic back pain to the emergency department. Emerg Med Australas. 2020;32(5):805–811.
for PBS-listed medicines at participating pharmacies.
Cultural safety
Engagement with Aboriginal Community Controlled Health Organisations (ACCHOs) is essential. Cultural safety training for non-Indigenous clinicians, use of Aboriginal Health Workers and Liaison Officers, and incorporation of traditional healing practices alongside Western medicine improve treatment adherence and outcomes. Avoidance of eye contact, respect for gender-sensitive examination practices, and understanding of sorry business protocols are critical elements of culturally safe care.
Medication adherence
Complex DMARD regimens with frequent monitoring requirements present adherence challenges. Long-acting depot injections (e.g., methotrexate SC) may improve adherence compared to oral regimens. Community pharmacy partnerships through the Indigenous Pharmacy Programmes improve medication management.
Specific conditions
Rheumatic heart disease (RHD) requires secondary prophylaxis with benzathine penicillin G (BPG) 1.2 MU IM every 3–4 weeks for a minimum of 10 years or until age 21 (whichever is longer). RHD registers (e.g., NT RHD Register) facilitate recall and follow-up. The Australian RHD Endgame Strategy targets elimination by 2031.
Referral pathways
Referral through ACCHOs and Aboriginal Hospital Liaison Officers (AHLOs) improves engagement. The Specialist Outreach Assistance Programme provides funded specialist visits to remote communities. NT, WA, and QLD have specific rheumatology outreach programmes targeting Indigenous communities.

📚 References

  1. 1. Australian Institute of Health and Welfare (AIHW). Autoimmune disease in Australia. Cat. no. PHE 312. Canberra: AIHW; 2023.
  2. 2. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2021;73(7):924–939.
  3. 3. Fanouriakis A, Kostopoulou M, Alber K, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736–745.
  4. 4. Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res. 2021;73(11):1583–1599.
  5. 5. Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3–18.
  6. 6. Australian Technical Advisory Group on Immunisation (ATAGI). Australian Immunisation Handbook. Australian Government Department of Health; 2024. Available from: immunisationhandbook.health.gov.au.
  7. 7. Rheumatic Heart Disease Australia (RHDAustralia). The 2020 Australian guideline for prevention, diagnosis, and management of acute rheumatic fever and rheumatic heart disease. 3rd ed. Darwin: Menzies School of Health Research; 2020.
  8. 8. Pharmaceutical Benefits Scheme (PBS). PBS Schedule. Australian Government Department of Health. Available from: pbs.gov.au. Accessed 2024.
  9. 9. Agarwal S, Cunnington J, Nossent J. Autoimmune disease in Indigenous Australians: a systematic review. Int J Rheum Dis. 2021;24(12):1487–1498.
  10. 10. Pisetsky DS. Antinuclear antibody testing — misunderstood or misused? Clin Immunol. 2023;255:109717.
  11. 11. Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771–1782.
  12. 12. Ledingham J, Deighton C; British Society for Rheumatology Standards, Audit and Guidelines Working Group. Update on the British Society for Rheumatology guidelines for prescribing TNFα blockers in adults with rheumatoid arthritis. Rheumatology. 2005;44(2):155–158.
  13. 13. National Health and Medical Research Council (NHMRC). National statement on ethical conduct in human research. Canberra: NHMRC; 2023 (updated).
for PBS-listed medicines at participating pharmacies.
Cultural safety
Engagement with Aboriginal Community Controlled Health Organisations (ACCHOs) is essential. Cultural safety training for non-Indigenous clinicians, use of Aboriginal Health Workers and Liaison Officers, and incorporation of traditional healing practices alongside Western medicine improve treatment adherence and outcomes. Avoidance of eye contact, respect for gender-sensitive examination practices, and understanding of sorry business protocols are critical elements of culturally safe care.
Medication adherence
Complex DMARD regimens with frequent monitoring requirements present adherence challenges. Long-acting depot injections (e.g., methotrexate SC) may improve adherence compared to oral regimens. Community pharmacy partnerships through the Indigenous Pharmacy Programmes improve medication management.
Specific conditions
Rheumatic heart disease (RHD) requires secondary prophylaxis with benzathine penicillin G (BPG) 1.2 MU IM every 3–4 weeks for a minimum of 10 years or until age 21 (whichever is longer). RHD registers (e.g., NT RHD Register) facilitate recall and follow-up. The Australian RHD Endgame Strategy targets elimination by 2031.
Referral pathways
Referral through ACCHOs and Aboriginal Hospital Liaison Officers (AHLOs) improves engagement. The Specialist Outreach Assistance Programme provides funded specialist visits to remote communities. NT, WA, and QLD have specific rheumatology outreach programmes targeting Indigenous communities.

📚 References

  1. 1. Australian Institute of Health and Welfare (AIHW). Autoimmune disease in Australia. Cat. no. PHE 312. Canberra: AIHW; 2023.
  2. 2. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2021;73(7):924–939.
  3. 3. Fanouriakis A, Kostopoulou M, Alber K, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736–745.
  4. 4. Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res. 2021;73(11):1583–1599.
  5. 5. Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3–18.
  6. 6. Australian Technical Advisory Group on Immunisation (ATAGI). Australian Immunisation Handbook. Australian Government Department of Health; 2024. Available from: immunisationhandbook.health.gov.au.
  7. 7. Rheumatic Heart Disease Australia (RHDAustralia). The 2020 Australian guideline for prevention, diagnosis, and management of acute rheumatic fever and rheumatic heart disease. 3rd ed. Darwin: Menzies School of Health Research; 2020.
  8. 8. Pharmaceutical Benefits Scheme (PBS). PBS Schedule. Australian Government Department of Health. Available from: pbs.gov.au. Accessed 2024.
  9. 9. Agarwal S, Cunnington J, Nossent J. Autoimmune disease in Indigenous Australians: a systematic review. Int J Rheum Dis. 2021;24(12):1487–1498.
  10. 10. Pisetsky DS. Antinuclear antibody testing — misunderstood or misused? Clin Immunol. 2023;255:109717.
  11. 11. Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771–1782.
  12. 12. Ledingham J, Deighton C; British Society for Rheumatology Standards, Audit and Guidelines Working Group. Update on the British Society for Rheumatology guidelines for prescribing TNFα blockers in adults with rheumatoid arthritis. Rheumatology. 2005;44(2):155–158.
  13. 13. National Health and Medical Research Council (NHMRC). National statement on ethical conduct in human research. Canberra: NHMRC; 2023 (updated).